Navigation Links
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
Date:9/7/2007

t groups by year two.

About EOquin

EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study which was completed earlier this year, EOquin instilled into the bladder following surgery was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, is expected to carry a low risk of systemic toxicity, if any.

Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced a 67% CR (complete response) in patients, many of whom had been treated multiple times. The data from this study were presented to the FDA in early 2006.

About Bladder Cancer

The American Cancer Society estimates that 67,160 new cases of bladder cancer will be found in the United States. According to Globocan Data estimates, approximately 147,000 new patients will be diagnosed with bladder cancer in Europe during 2007. The American Cancer Society estimates that approximately 13,750 people will die of this disease in the U.S. in 2007. Globocan Data estimates more than 53,000 will die in Europe in 2007. According to these sources, at any given time, it is estimated that there are more than 500,000 patients in the U.S. and more than 935 thousand patients in Europe. Non-invasive bladder cancer accounts for 75 to 80 percent of all cases of bladder cancer at first diagnosis. According to Botteman et al., (PharmacoEconomics 2003), bladder cancer is the fifth most expensive cancer to treat. The initial treatment of this cancer is surgical removal of the tumor. Because of the high frequency of early rec
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tech Digest: Firstlogic, Fiserv, Red Prairie, Spectrum Brands, Associated Bank
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
5. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
6. CIOs looking to hire more IT workers in second quarter
7. DNASTAR catches second wave of sequencing
8. 9 tips for making 90 seconds count in an investment pitch
9. City of Hope adds second TomoTherapy system
10. UW-Madison hybrid-vehicle team places second nationally
11. Just one nanosecond: Clocking events at the nanoscale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014 Deep Research Report on Global and ... study on the current state of the Nano Silver ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:7/11/2014)... PALM BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3
... Palatin Technologies, Inc. (NYSE Amex: PTN ... clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor ... the treatment of obesity. AZD2820 is a clinical candidate ... Palatin Technologies. Obesity is a global problem, ...
... 4, 2011   ReportsnReports announces ... Hospital-Acquired Infections (HAI) Diagnostics Market in its store ... for Alternatives to Needle-Based Systems for Vaccine and Biologics ... a focal point of competition within the pharmaceutical industry. The ...
... coatings devised by researchers from the National Institute of ... conventional flame retardants used in the polyurethane foam of ... and perhaps by as much as 1,130 percent. ... Polymer ,* suggest that significant fire-safety advantages can be ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 2ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 4Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... The ability to shrink laboratory-scale processes to automated ... example, inexpensive and highly portable devices that process ... anthrax are needed by the U.S. military and ... of "lab-on-a-chip" technology is the need for miniaturized ...
... from reproductive biologists at the University of Massachusetts Amherst, with ... sperm capacitation that may one day improve success rates of ... problems, and may eventually lead to a male contraceptive. ... down the road, says Pablo Visconti, lead UMass Amherst author, ...
... review suggests that omega-3 fatty acids taken in excess could ... standards based on the best available evidence need to be ... years ago may not be as clear cut as we ... Public Health and Human Sciences and a coauthor on the ...
Cached Biology News:Super-thin membranes clear the way for chip-sized pumps 2Reproductive biologists move in vitro fertilization knowledge forward 2Reproductive biologists move in vitro fertilization knowledge forward 3Excess omega-3 fatty acids could lead to negative health effects 2Excess omega-3 fatty acids could lead to negative health effects 3
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
... Macro-Prep ion exchange media are rigid ... allows high flow rates at moderate pressures, ... ionic sites, and the hydrophilic matrix reduces ... a high-capacity strong anion exchanger with very ...
Biology Products: